Analyst Price Target is $11.75
▲ +244.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Acelyrin in the last 3 months. The average price target is $11.75, with a high forecast of $20.00 and a low forecast of $6.00. The average price target represents a 244.57% upside from the last price of $3.41.
Current Consensus is
Moderate Buy
The current consensus among 4 polled investment analysts is to moderate buy stock in Acelyrin. This rating has held steady since June 2024, when it changed from a Hold consensus rating.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Read More
